GO:0007200 phospholipase C-activating G protein-coupled receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007200 describes a GPCR signaling pathway where receptor activation stimulates phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG).
• IP3 triggers calcium release from intracellular stores, while DAG and calcium activate protein kinase C (PKC), which phosphorylates downstream effectors.
• The pathway is critical for diverse physiological processes including smooth muscle contraction, neuronal signaling, immune responses, and hormone secretion.
• Dysregulation of PLC-activating GPCR signaling is implicated in cardiovascular disease, cancer, and metabolic disorders.
• Key experimental approaches include calcium imaging, phosphoinositide turnover assays, and genetic manipulation of receptors or G proteins.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of pathway components in disease-relevant cell types.
Description
The phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200) is a fundamental signal transduction cascade that converts extracellular stimuli into intracellular calcium signals and PKC activation. This pathway is initiated when an agonist binds to a G protein-coupled receptor (GPCR) that couples to Gq/11 family G proteins, leading to activation of phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG, two second messengers that orchestrate a wide range of cellular responses. The pathway is essential for many physiological processes, including smooth muscle contraction, secretion, neurotransmission, and cell proliferation. Researchers study this pathway to understand how GPCRs control calcium homeostasis and to develop therapeutics targeting cardiovascular, neurological, and metabolic diseases. The importance of this pathway is underscored by its evolutionary conservation and its involvement in both normal physiology and disease pathogenesis.
phospholipase C-activating G protein-coupled receptor signaling pathway At A Glance
| GO ID | GO:0007200 |
|---|---|
| GO term | phospholipase C-activating G protein-coupled receptor signaling pathway |
| Ontology | biological_process |
| Synonym | PLC-activating GPCR signaling pathway; G-protein coupled receptor signaling pathway coupled to IP3 second messenger; protein kinase C-activating G protein-coupled receptor signaling pathway |
| Major function | Transduces extracellular signals via Gq/11-coupled GPCRs to activate PLC, generating IP3 and DAG, which mobilize calcium and activate PKC. |
| Key second messengers | IP3 and DAG |
| Downstream effectors | Protein kinase C (PKC), calcium channels, and calcium-sensitive proteins |
| Cellular processes | Calcium signaling, smooth muscle contraction, secretion, neurotransmission, cell growth |
What Is GO:0007200?
GO:0007200 is defined as a G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 regulates the opening of calcium channels in intracellular calcium stores, leading to the release of calcium into the cytosol. Calcium and DAG activate protein kinase C (PKC), which in turn activates downstream effectors.
Why Is phospholipase C-activating G protein-coupled receptor signaling pathway Important in Cell Biology?
The phospholipase C-activating GPCR signaling pathway is a central mechanism for converting external signals into intracellular calcium transients and PKC activation, influencing processes as diverse as vascular tone, neuronal excitability, immune cell activation, and hormone release. Its dysregulation contributes to hypertension, heart failure, cancer, and neurological disorders, making it a prime target for drug discovery. Understanding this pathway at the molecular level is essential for developing selective therapeutics that modulate GPCR signaling with minimal side effects.
• Controls intracellular calcium release, a universal second messenger in cell physiology.
• Activates PKC, which regulates cell proliferation, differentiation, and apoptosis.
• Mediates smooth muscle contraction and vascular tone, relevant to hypertension.
• Modulates neuronal excitability and neurotransmitter release.
• Plays a role in immune cell activation and inflammatory responses.
• Involved in hormone secretion and metabolic regulation.
• Dysregulated in various cancers, contributing to tumor growth and metastasis.
• Target for drugs treating cardiovascular, psychiatric, and metabolic diseases.
• Provides a paradigm for understanding GPCR signal transduction and desensitization.
• Enables high-throughput screening for GPCR-targeted therapeutics.
What Happens During phospholipase C-activating G protein-coupled receptor signaling pathway?
Receptor Activation and G Protein Coupling
In simple terms: A signal molecule binds to a receptor on the cell surface, which then activates a helper protein inside the cell.
The pathway begins when an agonist binds to a Gq-coupled GPCR, such as the platelet-activating factor receptor or vasopressin V1 receptor. This induces a conformational change in the receptor that promotes the exchange of GDP for GTP on the Gαq subunit. The third intracellular domain of the receptor is a critical determinant for coupling to phosphoinositide PLC-activating G proteins. Receptor activation can be modulated by lateral mobility and desensitization mechanisms.
Phospholipase C Activation and Second Messenger Generation
In simple terms: The activated helper protein turns on an enzyme that cuts a membrane lipid into two messenger molecules.
Activated Gαq-GTP binds to and stimulates phospholipase C beta (PLCβ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). This reaction is a hallmark of the pathway and leads to a rapid increase in intracellular IP3 and DAG levels. PLC activation can be measured by phosphoinositide turnover assays.
Calcium Release and PKC Activation
In simple terms: One messenger opens calcium channels in the cell's storage compartments, releasing calcium, while the other messenger and calcium together activate an enzyme.
IP3 binds to IP3 receptors on the endoplasmic reticulum, triggering the release of stored calcium into the cytosol. The rise in cytosolic calcium, together with DAG, recruits and activates protein kinase C (PKC) at the plasma membrane. PKC then phosphorylates numerous downstream targets, including ion channels and transcription factors, to propagate the signal.
Downstream Effectors and Cellular Responses
In simple terms: The activated enzyme modifies other proteins, leading to changes in cell behavior.
PKC activation modulates the activity of ion channels, such as the human erg K+ channel, and influences gene expression, cell proliferation, and secretion. Calcium also activates calcium/calmodulin-dependent kinases and phosphatases, contributing to diverse cellular outcomes. The pathway can be desensitized by receptor phosphorylation and arrestin binding, as shown for receptor-regulated PLC.
Key Genes Involved in GO:0007200 phospholipase C-activating G protein-coupled receptor signaling pathway
The following genes and proteins are core components or regulators of the phospholipase C-activating GPCR signaling pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GNAQ | Encodes Gαq subunit that activates PLCβ | Mutations linked to uveal melanoma and vascular anomalies |
| GNA11 | Encodes Gα11 subunit, similar to Gαq | Mutations in uveal melanoma and hypercalcemia |
| PLCB1 | Phospholipase C beta 1, hydrolyzes PIP2 | Neurological disorders, epilepsy |
| PLCB2 | Phospholipase C beta 2, immune cell signaling | Inflammation, immune responses |
| PLCB3 | Phospholipase C beta 3, widely expressed | Cardiovascular function, cancer |
| PLCB4 | Phospholipase C beta 4, neuronal | Pain perception, synaptic plasticity |
| ITPR1 | IP3 receptor type 1, calcium channel | Spinocerebellar ataxia, calcium signaling |
| ITPR2 | IP3 receptor type 2 | Exocrine secretion, metabolic regulation |
| ITPR3 | IP3 receptor type 3 | Immune function, cancer |
| PRKCA | Protein kinase C alpha | Cancer, cardiac hypertrophy |
| PRKCB | Protein kinase C beta | Diabetic complications, immune disorders |
| PRKCG | Protein kinase C gamma | Neurodegeneration, spinocerebellar ataxia |
| AGTR1 | Angiotensin II receptor type 1, Gq-coupled | Hypertension, cardiovascular disease |
| AVPR1A | Vasopressin V1a receptor, Gq-coupled | Social behavior, blood pressure regulation |
| PTAFR | Platelet-activating factor receptor | Inflammation, allergy |
| EDNRA | Endothelin receptor type A | Pulmonary hypertension, cancer |
| HTR2A | Serotonin 2A receptor | Psychiatric disorders, drug discovery |
How Is phospholipase C-activating G protein-coupled receptor signaling pathway Regulated?
The pathway is tightly regulated at multiple levels. Receptor desensitization occurs via phosphorylation by G protein-coupled receptor kinases (GRKs) and subsequent arrestin binding, as demonstrated for receptor-regulated PLC. Heterologous desensitization can also occur through activation of other receptors. Additionally, the lateral mobility of the receptor in the membrane affects its coupling efficiency. Downstream, PKC activation can feedback to inhibit receptor signaling. Calcium signals are terminated by calcium pumps and exchangers that restore low cytosolic calcium levels. These regulatory mechanisms ensure appropriate signal duration and prevent cellular toxicity.
phospholipase C-activating G protein-coupled receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GNAQ | Uveal melanoma | Knock-in of mutant GNAQ in melanocytes |
| PLCB1 | Epilepsy, neurological disorders | Knockout in neuronal cell lines |
| AGTR1 | Hypertension | Overexpression in vascular smooth muscle cells |
| HTR2A | Schizophrenia, depression | Point mutation in serotonin receptor |
| ITPR1 | Spinocerebellar ataxia | Knockout in iPSC-derived neurons |
Cardiovascular Disease
The PLC-activating GPCR pathway is critical for vascular smooth muscle contraction and cardiac function. Overactivation of angiotensin II receptor (AGTR1) and endothelin receptor (EDNRA) contributes to hypertension and heart failure. Drugs targeting these GPCRs are mainstays of cardiovascular therapy. Dysregulation of calcium signaling in cardiomyocytes can lead to arrhythmias and hypertrophy.
Cancer
Mutations in GNAQ and GNA11 are frequent in uveal melanoma, leading to constitutive PLCβ activation and uncontrolled proliferation. Similarly, overexpression of PLCβ isoforms and PKC has been observed in various cancers, promoting tumor growth and metastasis. Targeting this pathway with small molecule inhibitors is an active area of oncology research.
Neurological and Psychiatric Disorders
The pathway modulates neuronal excitability and neurotransmitter release. Alterations in PLCβ1 and IP3 receptors have been linked to epilepsy, spinocerebellar ataxia, and bipolar disorder. Serotonin 2A receptor (HTR2A) signaling via PLC is a target for antipsychotic drugs, as explored in network pharmacology studies.
Metabolic and Endocrine Disorders
GPCRs coupled to PLC regulate insulin secretion, glucose homeostasis, and hormone release. For example, vasopressin V1a receptor signaling affects blood pressure and fluid balance. Drug-related gestational diabetes mellitus has been associated with modulation of such pathways, as identified in pharmacovigilance studies.
From phospholipase C-activating G protein-coupled receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GNAQ mutation drive tumor growth? | Knock-in of GNAQ Q209L in melanocytes |
| What is the role of PLCB1 in neuronal signaling? | PLCB1 knockout in SH-SY5Y cells |
| How does AGTR1 overexpression affect blood pressure? | Overexpression in vascular smooth muscle cells |
| Can a point mutation in HTR2A alter drug response? | Point mutation knock-in in HEK293 cells |
| What is the effect of ITPR1 deletion on calcium signaling? | ITPR1 knockout in HeLa cells |
| Does PKC alpha mediate cardiac hypertrophy? | PRKCA knockout in cardiomyocytes |
How to Study the phospholipase C-activating G protein-coupled receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium concentration | Live-cell GPCR activation |
| IP3 ELISA | IP3 levels | PLC activity quantification |
| Phospho-PKC western blot | PKC activation | Downstream signaling |
| CRISPR knockout | Gene function loss | Target validation |
| CRISPR knock-in | Mutant protein expression | Disease modeling |
| RNA-seq | Transcriptional changes | Pathway profiling |
| Network pharmacology | Drug-target interactions | Therapeutic discovery |
Calcium Imaging
Calcium imaging using fluorescent dyes (e.g., Fura-2, Fluo-4) or genetically encoded calcium indicators (GECIs) allows real-time measurement of intracellular calcium release upon GPCR activation. This method is widely used to assess PLC-activating GPCR function in live cells.
Phosphoinositide Turnover Assays
Radioactive or fluorescent labeling of phosphoinositides followed by agonist stimulation measures PLC activity by quantifying IP3 production or PIP2 hydrolysis. These assays are standard for evaluating receptor coupling to PLC.
Western Blotting and Phospho-antibodies
Detection of phosphorylated PKC substrates or downstream effectors (e.g., ERK) by western blot provides a readout of pathway activation. This method is useful for validating genetic manipulations.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 enables knockout, knock-in, or point mutation of genes encoding GPCRs, G proteins, PLC isoforms, or PKC. These models help dissect the specific contributions of each component to pathway function and disease.
How CRISPR Can Be Used to Study GO:0007200 phospholipase C-activating G protein-coupled receptor signaling pathway
Knockout
CRISPR knockout of genes such as GNAQ, PLCB1, or PRKCA eliminates protein function, allowing researchers to assess their necessity in the PLC-activating GPCR pathway. For example, PLCB1 knockout in neuronal cells can reveal its role in calcium signaling and neurotransmitter release.
Point Mutation
Introducing specific point mutations (e.g., GNAQ Q209L) via CRISPR knock-in mimics disease-associated variants. These models help study constitutive activation of the pathway and test targeted inhibitors.
Knock-in
Knock-in of tagged versions of receptors or G proteins (e.g., GFP-tagged AGTR1) enables live-cell imaging and protein interaction studies. This approach is valuable for tracking receptor trafficking and desensitization.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of wild-type or mutant receptors (e.g., HTR2A) can amplify pathway signaling, useful for drug screening and studying gain-of-function phenotypes.
How EDITGENE Supports phospholipase C-activating G protein-coupled receptor signaling pathway Research
Researchers studying phospholipase C-activating G protein-coupled receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in a specific cellular response or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for phospholipase C-activating G protein-coupled receptor signaling pathway research.
Frequently Asked Questions About phospholipase C-activating G protein-coupled receptor signaling pathway
What is GO:0007200?
GO:0007200 is the Gene Ontology term for the phospholipase C-activating G protein-coupled receptor signaling pathway, a biological process where GPCR activation leads to PLC stimulation, IP3 and DAG production, calcium release, and PKC activation.
What genes are involved in phospholipase C-activating GPCR signaling?
Key genes include GNAQ, GNA11, PLCB1-4, ITPR1-3, PRKCA/B/C, and various GPCRs such as AGTR1, AVPR1A, and HTR2A.
How does the PLC-activating GPCR pathway work?
An agonist binds a Gq-coupled GPCR, activating Gαq, which stimulates PLC to hydrolyze PIP2 into IP3 and DAG. IP3 releases calcium from the ER, and calcium with DAG activates PKC.
What diseases are associated with PLC-activating GPCR signaling?
Dysregulation is linked to cardiovascular disease, cancer (e.g., uveal melanoma), neurological disorders, and metabolic conditions like diabetes.
What are common methods to study this pathway?
Calcium imaging, IP3 assays, phospho-PKC western blotting, and CRISPR-based gene editing are widely used.
Can CRISPR be used to study PLC-activating GPCR signaling?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of pathway components to study their function and disease relevance.
What is the role of PKC in this pathway?
PKC is activated by calcium and DAG and phosphorylates downstream targets, influencing cell proliferation, differentiation, and secretion.
How is the pathway desensitized?
Receptor phosphorylation by GRKs and arrestin binding mediate desensitization, as shown for receptor-regulated PLC.
What cell models are suitable for studying this pathway?
HEK293, HeLa, SH-SY5Y, vascular smooth muscle cells, and iPSC-derived neurons are commonly used.
How can EDITGENE help with my research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening services tailored to GPCR signaling research.
Conclusion
The phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200) is a cornerstone of cellular signal transduction, linking extracellular cues to calcium mobilization and PKC activation. Its widespread involvement in physiology and disease makes it a focal point for biomedical research. Advances in CRISPR genome editing and functional assays continue to unravel the complexities of this pathway, offering new opportunities for therapeutic intervention. EDITGENE's specialized services empower researchers to dissect this pathway with precision and efficiency.
References
- 1. Carlson SA et al.. 1996. The third intracellular domain of the platelet-activating factor receptor is a critical determinant in receptor coupling to phosphoinositide phospholipase C-activating G proteins. Studies using intracellular domain minigenes and receptor chimeras.. J Biol Chem 271(38):23146-53 PMID: 8798508
- 2. Eichstaedt S et al.. 2008. Phospholipase C-activating plasma membrane receptors and calcium signaling in immortalized human airway epithelial cells.. J Recept Signal Transduct Res 28(6):591-612 PMID: 19096976
- 3. Jans DA et al.. 1990. Lateral mobility of the phospholipase C-activating vasopressin V1-type receptor in A7r5 smooth muscle cells: a comparison with the adenylate cyclase-coupled V2-receptor.. EMBO J 9(9):2693-9 PMID: 2143982
- 4. Barros F et al.. 1998. Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C.. J Physiol 511 ( Pt 2)(Pt 2):333-46 PMID: 9706014
- 5. Jing H et al.. 2026. Risk factors for drug-related gestational diabetes mellitus: a real-world pharmacovigilance study based on the FAERS database.. BMC Pregnancy Childbirth 26(1) PMID: 42092831
- 6. Khanh Nguyen NP et al.. 2024. Antidepressant and anxiolytic potential of Citrus reticulata Blanco essential oil: a network pharmacology and animal model study.. Front Pharmacol 15:1359427 PMID: 38567354
- 7. Galas MC et al.. 1995. Receptor-induced heterologous desensitization of receptor-regulated phospholipase C.. Eur J Pharmacol 291(2):175-82 PMID: 8566168
- 8. Yang L et al.. 2024. Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking.. Schizophrenia (Heidelb) 10(1):105 PMID: 39511179
